Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 2, 2015, Pages 408-414

  De Rotte, Maurits C F J ^a   Den Boer, Ethan ^a   De Jong, Pascal H P ^a   Pluijm, Saskia M F ^a   Bulatović Ćalasan, Maja ^b   Weel, Angelique E ^c   Huisman, A Margriet ^d   Gerards, Andreas H ^e   Van Schaeybroeck, Barbara ^f   Wulffraat, Nico M ^b   Lindemans, Jan ^a   Hazes, Johanna M W ^a   De Jonge, Robert ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Maasstad Hospital   (Netherlands)

^d IJSSELLAND HOSPITAL   (Netherlands)

^e Vlietland Hospital   (Netherlands)

^f ALBERT SCHWEITZER HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; GLUCOCORTICOID; GLUTAMIC ACID; HYDROXYCHLOROQUINE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; POLYGLUTAMIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BONE MARROW DEPRESSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MONITORING; ERYTHROCYTE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALAISE; MALE; MASS SPECTROMETRY; MENTAL DISEASE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; CHEMISTRY; COHORT ANALYSIS; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHROMATOGRAPHY, LIQUID; COHORT STUDIES; ERYTHROCYTES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; POLYGLUTAMIC ACID; TANDEM MASS SPECTROMETRY;

EID: 84921311336     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203725     Document Type: Article

References (25)

1. Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics 2011;12:1449-63.
2. Stamp LK, O'Donnell JL, Chapman PT, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010;62:359-68.
3. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
4. Hornung N, Ellingsen T, Attermann J, et al. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. J Rheumatol 2008;35:1709-15.
5. Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:3299-308.
6. Bannwarth B, Pehourcq F, Schaeverbeke T, et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996;30:194-210.
7. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford) 2010;49:2337-45.
8. Stamp LK, O'Donnell JL, Chapman PT, et al . Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 2009;60:2248-56.
9. Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999;17:313-20.
10. Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180-5.
11. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006;54:3095-103.
12. Hobl EL, Jilma B, Erlacher L, et al. A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol 2012;30:156-63.
13. Bulatovic Calasan M, Den Boer E, De Rotte MCFJ, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthrits patients. Ann Rheum Dis 2015;74:402-7.
14. Becker ML, Gaedigk R, van Haandel L, et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011;63:276-85.
15. Dolezalova P, Krijt J, Chladek J, et al. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology (Oxford) 2005;44:74-9.
16. de Rotte MC, Luime JJ, Bulatovic M, et al. Do snapshot statistics fool us in MTX pharmacogenetic studies in arthritis research? Rheumatology (Oxford) 2010;49:1200-1.
17. Claessen SJ, Hazes JM, Huisman MA, et al. Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. BMC Musculoskelet Disord 2009;10:71.
18. de Jong PH, Hazes JM, Barendregt PJ, et al. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 2013;72:72-8.
19. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
20. den Boer E, Meesters RJ, Van Zelst BD, et al. Measuring methotrexate polyglutamates in red blood cells: a new LC-MS/MS based method. Anal Bioanal Chem 2013;405:1673-81.
21. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
22. van Gestel AM, Prevoo ML, van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
23. Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
24. Brooks AJ, Begg EJ, Zhang M, et al. Red blood cell methotrexate polyglutamate concentrations in in flammatory bowel disease. Ther Drug Monit 2007;29:619-25.
25. Ortiz Z, Shea B, Suarez Almazor M, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000;(2):CD000951.